Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

of leasehold

improvements - - 1,030

Depreciation and amortization 297 321 3,115

In-process research and

development - - 418

Total operating expenses 10,232 12,448 144,638

Loss from operations (10,232) (9,288) (139,694)

Other income (expenses):

Interest income 693 1,702 9,643

Interest expense (92) (70) (1,500)

Change in fair value of

warrant liability (64) - (454)

Other expense - - (1,180)

Loss before tax benefit (9,695) (7,656) (133,185)

(Provision for)/benefit

from income taxes - (75) 620

Net loss (9,695) (7,731) (132,565)

Deemed dividend - - (19,424)

Preferred stock accretion (41) - (802)

Net loss attributable to

common stockholders $(9,736) $ (7,731) $(152,791)

Net loss attributable to

common stockholders per

common share - basic and

diluted $ (10.21) $(0.34)

Weighted-average common

shares outstanding -

basic and diluted 953,959 22,412,689

See accompanying notes to consolidated financial statements

Table 2

Amicus Therapeutics, Inc.

Reconciliation of GAAP to non-GAAP Measures for the Statement of Operations Information for Three Months Ended March 31, 2008

(Unaudited)

(In thousands, except share and per share amounts) <
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... South Carolina (PRWEB) July 29, 2014 DisasterTalk ... teams of people where cell phone masts or other transmitters ... up to 100 feet away without the need for any ... target longer ranges. , The new app has launched as ... US homes are at very high risk of being affected ...
(Date:7/29/2014)... G-CON Manufacturing Inc., the standard in design and ... leadership appointment designed to drive the company’s ambitious growth ... Maik Jornitz, Chief Operating Officer of G-Con Manufacturing, has ... the pioneering company through its next phase of market ... and look forward to providing our next generation of ...
(Date:7/29/2014)... The prestigious "Discovery or Exploration in History Award" ... Juliana Hillis and Kaylie O’Connell, students at Stoneham High ... Egg, Everything: America’s First IVF Baby". This project was ... History Day program during a week-long final competition judged ... D.C. , The growing popularity of the assisted reproductive ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 EXpressLO LLC, ... lift out specimen preparation solutions, has been granted patent ... for specimen manipulation methods incorporating a unique specimen carrier ... This is the second company patent for EXpressLO LLC ... , These complementary patents extend EXpressLO’s portfolio ...
Breaking Biology Technology:DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2
... at the helm of several companies, Michael Flavin, CEO of ... Ill. across from Argonne National Laboratory ), sees a ... , ,Following a six-month preparation period, Flavin says hell ... financial adviser Legg Mason to raise about $30 ...
... - Automating Peripherals Inc announced that the company's ... standards mandated by the Health Insurance Portability and ... on Accreditation of Healthcare Organizations (JCAHO). SecurALL is ... regulate and monitor facility access throughout an organization ...
... Pilots of F-18s have been using the technology for years ... Soon, automobile drivers will get a similar view with speed, ... their windshield. The goal of the heads-up display is to ... , ,"For many of the distractions that can lead to ...
Cached Biology Technology:Advanced Life Sciences to Hit the Road For $30 Million in Funding 2Advanced Life Sciences to Hit the Road For $30 Million in Funding 3Advanced Life Sciences to Hit the Road For $30 Million in Funding 4
(Date:7/28/2014)... tool that can help advance the genetic engineering ... bioenergy, has been developed by researchers with the ... (JBEI), a multi-institutional partnership led by Lawrence Berkeley ... developed an assay that enables scientists to identify ... critical components in the biosynthesis of plant cell ...
(Date:7/28/2014)... to prevent and treat HIV infection has been problematic ... molecules can arouse as they get rid of the ... Weizmann Institute and the National Institutes of Health (NIH) ... interferons around the time of infection could ... Their research appeared in Nature . , ...
(Date:7/28/2014)... at Harvard University today announced that its human ... formed private company to accelerate development of pharmaceutical, ... The announcement follows a worldwide license agreement between ... start-up Emulate Inc., relating to the use of ... "This is a big win towards achieving our ...
Breaking Biology News(10 mins):How sweet it is 2How sweet it is 3Interfering with interferon 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3
... IOF Medal of Achievement was awarded today at the ... A. Kanis. The award honours an individual ... through original and outstanding scientific work. It underlines an ... and awareness of osteoporosis and to promote medical innovation, ...
... of the Walter and Eliza Hall Institute from 1996-2009 ... the institute,s Molecular Genetics of Cancer division. The ... Doug Hilton, said he was delighted Professor Cory had ... are immensely proud of this latest of Suzanne,s achievements," ...
... -- With thousands of scientists across the globe searching for ... a growing emphasis on finding the "master regulators" that guide ... and the University of Cambridge suggests that a closely connected ... cells (HSCs), the self-renewing cells the body uses to make ...
Cached Biology News:Suzanne Cory becomes first-elected woman president of AAS 2Stem cells: In search of a master controller 2
ID clarifier: With ethidium bromide (50 μg/ml)...
... Pre-tested for optimal colony ... the growth of anchorage-dependent ... methylcellulose colony-forming assays of ... cells. Not suitable for ...
... A simultaneous dual parameter assay ... poly caspase activity. Active caspases are ... peptide inhibitors, which are cell-permeable, non-cytotoxic ... caspases within the cells. At the ...
... be induced prior to DNA purification increasing ... of single-copy BACs with the high yields ... The kits provide the linearized vector and ... system) necessary to create a 10X human ...
Biology Products: